Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Date:8/19/2007

SAN DIEGO, Aug. 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today unaudited financial results for the second quarter and six months ended June 30, 2007. Cadence reported a net loss for the second quarter of 2007 of $14.9 million, or $0.52 per share, compared to a net loss of $6.2 million, or $4.92 per share, in the second quarter of 2006. For the six months ended June 30, 2007, the company reported a net loss of $24.5 million, or $0.86 per share, compared to a net loss of $35.4 million, or $28.50 per share for the six months ended June 30, 2006.

As of June 30, 2007, Cadence held cash and cash equivalents of $66.9 million.

"We remain keenly focused on executing the development programs for our two Phase III product candidates, intravenous acetaminophen and Omigard(TM)," said Ted Schroeder, Cadence's President and Chief Executive Officer. "As a result, we are on track to meet our clinical development and pre-commercialization manufacturing objectives for both product candidates. In particular, we are pleased with the recent execution of a development and supply agreement for IV acetaminophen with Baxter Healthcare, a leading global contract manufacturer, which we believe will position us to meet the anticipated demand for this important product candidate upon commercialization and for several years thereafter."

Financial Results

Total operating expenses for the second quarter of 2007 were $15.7 million, compared to $6.6 million for the second quarter of 2006. The increase in operating expenses was p
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 30, 2015   Pharnext SAS today announced ... for the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being ... 2015 Peripheral Nerve Society (PNS) Biennial Meeting at the Quebec ... June 27 - July 2, 2015. At Poster ... July 1, 5p.m. to 7p.m. EDT: Poster ...
(Date:6/29/2015)... ... June 29, 2015 , ... The global microfluidics market ... forecast period (2015 to 2020). The market is mainly driven by the rising ... for R&D. However, lack of adequate healthcare and research infrastructure in emerging markets, ...
(Date:6/29/2015)... 2015  AACC, a global scientific and medical ... medicine, is pleased to announce that the impact ... has increased to 7.9 in the 2014 Thomson ... Clinical Chemistry in the top 3% of ... of the research it publishes on laboratory medicine ...
(Date:6/29/2015)... 2015  Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical ... molecule and cell therapy treatments for central nervous system ... listing on the NASDAQ Capital Market under the symbol ... on the NYSE MKT until the market close on ... is expected to commence on July 13, 2015. ...
Breaking Biology Technology:Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3
... Green Bay, Wis - Mark Green's economic ... sweeping proposal would eliminate the state Department of Commerce ... ,Amid a series of ideas that include revenue caps, employer ... in much the same way that Indiana Gov. Mitch ...
... Madison, Wis. - Small businesses interested in tapping into ... able to learn what it takes to win these competitive ... in the entrepreneurial sector are encouraged to attend the ... 9 at the Hilton Milwaukee City Center . , ...
... to ramp up soybean oil production for use in ... , ,The state grant, presented this week to Quality ... than double its capacity to produce soybean oil, and ... like Renewable Alternatives. , ,Quality Roasting's soybean crushing operation ...
Cached Biology Technology:Green economic plan takes cue from Indiana 2Green economic plan takes cue from Indiana 3Green economic plan takes cue from Indiana 4Wisconsin's biodiesel network expands 2
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market announces that ... featured segment on "Money on the Mark", scheduled to air ... June 20 th . The ... be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/16/2015)... June 16, 2015 /CNW Telbec/ - handyem Inc. ... around the incorporation of handyem,s HPC-150 portable flow ... the Mo-POD™. This unprecedented model of mobile laboratory ... at the Pennsylvania Convention ... 15 th to 18 th 2015. ...
(Date:6/15/2015)... 15, 2015 A new report [ ... the majority of US consumers using mobile banking applications want ... as fingerprint and voiceprint, instead of having to prove who ... Telstra,s " Mobile Identity   -   The Fusion of ... smartphones now the primary channel used by Gen X and ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... DE This month, Molecular Pharmaceutics ... Childhood Cancer Research and the Materials Science and ... the potential for nanotechnology to deliver chemotherapeutic agents ... harming healthy cells. To date, nanoparticle-based drug delivery ...
... For the first time, researchers have demonstrated that the ... glioblastoma virotherapy, a novel way of treating malignant brain ... A number of clinical trials are currently underway to ... research led by E. Antonio Chiocca, MD, PhD, chairman ...
... the University of Southampton has shown that copper ... contributed to the increasing number of antibiotic-resistant infections ... is largely responsible for the development of antibiotic-resistance, ... difficult-to-treat healthcare-associated infections (HCAIs). The newly-published paper, ...
Cached Biology News:Nanotechnology drug delivery shows promise for treatment of pediatric cancer 2New study shows how copper restricts the spread of global antibiotic-resistant infections 2
NF kappa B Related Sampler Kit 10g each...
Homo sapiens MEP50 protein, mRNA...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Biology Products: